Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AryoGen dupilumab versus Dupixent in moderate to severe atopic dermatitis
IRCT20150303021315N37Phase 3Recruiting
- Sponsor
- AryoGen Biopharma
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dupilumab in atopic dermatitis (AD) (2 arms), sponsored by AryoGen Biopharma. Primary endpoints: Eczema Area and Severity Index, Investigator's Global Assessment and 2 more. Started Nov 2025; status: recruiting.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on IRCT20150303021315N37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150303021315N37.